Bénéficiaires de la subvention à l'innovation

Le Fonds de la subvention à l'innovation en recherche vise à susciter des idées créatrices et originales, pour pallier le sous-financement de la recherche sur le cancer du pancréas.

Nous sommes résolus à attirer de nouveaux talents et à soutenir des chefs de file de la recherche dans cette discipline dans l'espoir d'en arriver à une masse critique pour l'étude de la maladie.

Grâce à notre Conseil consultatif médical, qui réunit d'éminents spécialistes du cancer du pancréas de partout au Canada, nous nous assurons que le financement contribue à la réalisation des meilleures recherches.

2014 Bénéficiaires de la subvention à l'innovation

Pour en savoir plus sur les projets et les chercheurs que nous finançons actuelle:

 Dr. Sachdev Sidhu - University of Toronto

Study - Development and characterization of synthetic antibodies against pancreatic cancer targets

Dr. Sidhu was recruited to the University of Toronto in 2008 after spending ten years as a Principal Investigator at Genentech, Inc., where he led the development of phage-displayed synthetic antibody libraries that have since proven to be a rich source of valuable reagents for basic research and potential therapeutics. Dr. Sidhu’s interests lie in the relationships between protein structure and function, and he is an expert in phage display technology and structure-based and combinatorial protein engineering. His research has been instrumental in establishing greatly improved technologies for therapeutic antibody development using high throughput screening and structure-guided phage library construction. In 2010, Dr. Sidhu led the creation of the Toronto Recombinant Antibody Centre (TRAC), an integrated laboratory with a state-of-the­art, high throughput antibody platform that can be applied to the generation of therapeutic-grade antibodies against virtually any protein. The TRAC has enabled the generation of thousands of antibodies with desired characteristics of affinity and specificity. In 2014, Dr. Sidhu’s expertise and innovation in the therapeutic antibody and protein engineering fields was acknowledged with an award from the Canadian Government to open the Centre for the Commercialization of Antibodies and Biologics (CCAB), as part of the Networks of Centres of Excellence program. Dr. Sidhu was also granted the University of Toronto’s Inventor of the Year Award in 2012. 

Igor Stagljar - University of Toronto

Study - Elucidation of aberrant K-RAS signaling pathways in Pancreatic Ductal Adenocarcinoma (PDAC) using MaMTH, a novel proteomics technology 

Igor Stagilar is a Croatian-born Canadian scientist who currently works as a Professor of Molecular Genetics and Biochemistry at Donnelly Centre at the Medical School of the University of Toronto.

Amongst his most significant scientific achievements to date is the development of two proteomics technologies called MYTH (Membrane Yeast Two-Hybrid) and MaMTH (Mammalian Membrane Two-Hybrid). This has led to many groundbreaking discoveries and the elucidation of functions of various membrane proteins involved in human health and disease. His current work focuses on mapping of protein interactions and molecular networks of numerous proteins of therapeutic importance as well as understanding the mechanisms of drugs relevant for various types of cancer and cystic fibrosis.

Study - Cellular Origins of Pancreatic Ductal Adenocarcinoma

Dr. Janel Kopp is a newly recruited Assistant Professor in the Department of Cellular & Physiological Sciences at the University of British Columbia. She is also an affiliate member of the Department of Pathology and Laboratory Medicine and a team member of the Pancreas Centre BC. Dr. Kopp’s laboratory research is focused on understanding the cellular and molecular mechanisms underlying the development of pancreatic cancer.

Ralph DaCosta - Cancer Care Ontario Research Chair in Cancer Imaging 

Study - Synchronous radiotherapy enhancement of pancreatic cancer with xray induced photodynamic therapy and oxygen generating nanoparticles 

Dr. Daniel Renouf - BC Cancer Agency

Study - The effects of neoadjuvant metformin on  tumour cell proliferation and tumour progression in pancreatic ductal adenocarcinoma 

Daniel Renouf is a medical oncologist at the British Columbia Cancer Agency, Vancouver Centre, and an Assistant Professor at the University of British Columbia, Department of Medicine. 

He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and British Columbia Cancer Agency.  He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto, and obtained a Masters of Public Health from Harvard University. 

Daniel’s research interests include developmental therapeutics, genomics, and biomarker development within gastrointestinal cancers, with a focus on pancreatic cancer.  He is the leader of the BC Cancer Agency Phase I program, and is the Co-Director of Pancreas Centre BC.